Good morning. Elizabeth Cooney here, subbing for Ed Silverman today and tomorrow from a satellite campus near Boston where the mascots are feline, the tall people decamped to New York long ago, and the coffee is always French roast (black). Some news to get you going:
Novartis (NVS) has announced positive results from trials testing its daily fixed dose treatment of a two-drug combination for people with uncontrolled asthma, QMF149, and its triple combination, QVM149, Pharmaphorum says. Both drugs are under review by the European Medicines Agency after more than a decade of clinical development at Novartis, which acquired rights to QMF149 in 2009 from Schering-Plough.